Human papillomavirus in high-grade cervical lesions: Austrian data of a European multicentre study

Wiener Klinische Wochenschrift

Volumn 125, Issue 19-20, 2013, Pages 591-599

  Rössler, Lucia ^a   Reich, Olaf ^b   Horvat, Reinhard ^c   De Souza, Sabrina Collas ^d   Holl, Katsyarina ^e   Joura, Elmar A ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d GLAXOSMITHKLINE   (France)

^e GSK   (Belgium)

Author keywords

Cervical cancer; Cervical dysplasia ; Epidemiology ; HPV high risk types ; Human papillomavirus

Indexed keywords

ADULT; AGED; ALPHAPAPILLOMAVIRUS; ARTICLE; AUSTRIA; CANCER GRADING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN TISSUE; POLYMERASE CHAIN REACTION; UTERINE CERVIX CARCINOMA IN SITU; UTERUS CARCINOMA;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COMORBIDITY; EUROPE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM GRADING; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84886952117     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-013-0403-6     Document Type: Article

References (34)

1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
2. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32(Suppl 1):S16-24.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55:74-108.
4. Regauer S, Reich O. CK17 and p16 expression patterns distinguish (atypical) immature squamous metaplasia from high-grade cervical intraepithelial neoplasia (CIN III). Histopathology. 2007;50(5):629-35.
5. Reich O, Pickel H, Regauer S. Why does HPV infection induce sharply demarcated lesions of the cervix? J Low Genit Tract Dis. 2008;12:8-10.
6. Reich O, Pickel H. Multifocal stromal invasion in microinvasive squamous cell carcinoma of the cervix: how to measure and stage these lesions. Int J Gynecol Pathol. 2002;21:416-7.
7. Reich O, Pickel H, Tamussino K, Winter R. Microcarcinoma of the cervix: first focus of invasion. Obstet Gynecol. 2001;97:890-2.
8. McCredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008;9(5):425-34.
9. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621-32.
10. Tjalma WA, Fiander A, Reich O, et al.; HERACLES/SCALE Study Group. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int J Cancer. 2013;132(4):854-67.
11. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17(8):857-72.
12. Zechmeister I. Ökonomische Evaluation der Impfung gegen humane Papillomaviren (HPV- Impfung) in Österreich. Endbericht des Ludwig Boltzmann Instituts für Health Technology Assessment (LBI-HTA) 2007;26.
13. Leitner B. Statistik Austria, Jahrbuch der Gesundheitsstatistik 2010. Vienna: Statistik Austria; 2011.
14. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006;367(9509):489-98.
15. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.
16. Van Hentenryck M, Noel JC, Simon P. Obstetric and neonatal outcome after surgical treatment of cervical dysplasia. Eur J Obstet Gynecol Reprod Biol. 2012;162(1):16-20.
17. Ortoft G, Henriksen T, Hansen E, Petersen L. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. BJOG. 2010;117(3):258-67.
18. Six L, Leodolter S, Sings HL, Barr E, Haupt R, Joura EA. Prevalence of Human Papillomavirus Types 6, 11, 16, and 18 in young Austrian Women- the baseline data of a Phase III Vaccine Trial. Wien Klin Wochenschr. 2008;120(21-22):666-71.
19. Herzog TJ, Monk BJ. Reducing the burden of glandular carcinomas of the uterine cervix. Am J Obstet Gynecol. 2007;197(6):566-71.
20. Bray F, Carstensen B, Møller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev. 2005;14(9):2191-9.
21. Zielonke N. Krebsinzidenz und Krebsmortalität in Österreich 2012. Vienna: Statistik Austria; 2012.
22. Ault KA, Joura EA, Kjaer SK, et al.; FUTURE I and II Study Group. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer. 2011;128(6):1344-53.
23. Stoler MH, Vichnin MD, Ferenczy A, et al.; FUTURE I, II and III Investigators. The accuracy of colposcopic biopsy: analyses from the placebo arm of the Gardasil clinical trials. Int J Cancer. 2011;128(6):1354-62.
24. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol. 2006;44:3292-8.
25. van Doorn LJ, Quint W, Kleter B, et al. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol. 2002;40:979-83.
26. Paavonen J, Naud P, Salmerón J, et al.; HPV PATRICIA Study Group. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374(9686):301-14.
27. Lehtinen M, Paavonen J, Wheeler CM, et al.; HPV PATRICIA Study Group. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89-99.
28. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
29. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials. Lancet. 2007;369:1693-702.
30. Joura EA, Garland SM, Paavonen J, et al.; FUTURE I and II Study Group. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ. 2012;27(344):e1401.
31. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926-35.
32. Wheeler CM, Castellsagué X, Garland SM, et al. HPV PATRICIA Study Group. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100-10.
33. Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781-9.
34. Canfell K, Chesson H, Kulasingam SL, Berkhof J, Diaz M, Kim JJ. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine. 2012;30 Suppl 5:F157-67.